UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR (737) 255-7194 (Registrant's telephone number, including area code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. (Exact name of registrant as sp ...

Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Conference Call April 20, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial Officer Conference Call Participants Justin Walsh - Jones Trading Sean Lee - HC Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics First Quarter 2023 Results Conference Call. Before we begin, we want to a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 33-0827593 (State or other jurisdi ...

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants Marc Hedrick - President and Chief Executive Officer Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial Officer Conference Call Participants Justin Walsh - Jones Trading Edward Woo - Ascendiant Capital Sean Lee - HC Wainwright Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Fourth Quarter and Full Year 2022 Results Conference Call. Before ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) DELAWARE 33-0827593 (State or Other Jurisdiction ...

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2022 Earnings Conference Call October 20, 2022 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial Officer Conference Call Participants Justin Walsh - Jones Trading Edward Woo - Ascendiant Sean Lee - HC Wainwright Brandon Carney - B. Riley Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Third Quarter 2022 Results Call. Before we beg ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 33-0827593 (State or other jur ...

The ReSPECT-GBM Phase 1/2a Trial of Rhenium-186 NanoLiposome ( 186RNL) in Recurrent Glioma via Convection-Enhanced Delivery (CED) Abstract 277O Andrew J. Brenner1, Ande Bao1, William Phillips1, Joel E. Michalek1, Marc H Hedrick2, Norman LaFrance2, Toral R. Patel3, Jeffrey S. Weinberg4, John Floyd1 1Mays Cancer Center at UT Health San Antonio, Texas, USA 9 September 2022; 2Plus Therapeutics, Austin, TX USA; 3UT Southwestern, Dallas Texas, USA; 4MD Anderson Cancer Center, Houston, TX, USA | --- | --- | --- | ...

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q2 2022 Results Conference Call July 21, 2022 5:00 PM ET Company Participants Dr. Marc Hedrick - President and Chief Executive Officer Dr. Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial Officer Conference Call Participants Michael Rabinowitz - Maxim Group Ed Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Second Quarter 2022 Results Call. Before we begin, we want to advise you that over the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of registrant as specified in its charter) Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. DELAWARE 33-0827593 (State or other jurisdic ...